IP Library Granted Patent US 7,504,107
Granted Patent B2
US 7,504,107 · App. 11/935,188 · Granted Mar 17, 2009

Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response

Assignee: MedImmune, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,504,107
App. No.
11/935,188
Granted
Mar 17, 2009
Kind
B2
Abstract

Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.

Claims (50)

1. A process for priming the immunogenic activity of a vaccine, comprising:

(a) administering to an animal in need thereof an effective amount of an antibody specific for one or more of the antigenic determinants characteristic of said vaccine useful against a toxin and whose immunogenic activity is to be primed; and

(b) administering to said animal an effective amount of the vaccine, of step (a);

wherein said vaccine comprises at least one antigenic determinant for which the antibody of step (a) is not specific.

2. The process of claim 1 , wherein step (a) is carried out at least 24 hours before step (b).

3. The process of claim 1 , wherein step (a) is carried out at least 1 week before step (b).

4. The process of claim 1 , wherein the antibody is specific for more than one antigenic determinant present in the vaccine.

5. The process of claim 1 , wherein the effective amount of antibody is in the range of 5 to 20 mg/kg of body weight.

6. The process of claim 1 , wherein the effective amount of vaccine is between about 5 μg per kg of body weight to about 1 gram per kg body weight.

7. A process for priming the immunogenic activity of a vaccine, comprising:

(a) administering to an animal in need thereof an effective amount of an antibody specific for one or more of the antigenic determinants characteristic of said vaccine useful against a bacterium and whose immunogenic activity is to be primed; and

(b) administering to said animal an effective amount of the vaccine, of step (a);

wherein said vaccine comprises at least one antigenic determinant for which the antibody of step (a) is not specific.

8. The process of claim 7 , wherein step (a) is carried out at least 24 hours before step (b).

9. The process of claim 7 , wherein step (a) is carried out at least 1 week before step (b).

10. The process of claim 7 , wherein the antibody is specific for more than one antigenic determinant present in the vaccine.

11. The process of claim 7 , wherein the effective amount of antibody is in the range of 5 to 20 mg/kg of body weight.

12. The process of claim 7 , wherein the effective amount of vaccine is between about 5 μg per kg of body weight to about 1 gram per kg body weight.

13. A process for priming the immunogenic activity of a vaccine, comprising:

(a) administering to an animal in need thereof an effective amount of an antibody specific for one or more of the antigenic determinants characteristic of said vaccine which elicits an immunogenic response and whose immunogenic activity is to be primed; and

(b) administering to said animal an effective amount of the vaccine, of step (a);

wherein said vaccine comprises at least one antigenic determinant for which the antibody of step (a) is not specific.

14. The process of claim 13 , wherein step (a) is carried out at least 24 hours before step (b).

15. The process of claim 13 , wherein step (a) is carried out at least 1 week before step (b).

16. The process of claim 13 , wherein the antibody is specific for more than one antigenic determinant in the vaccine.

17. The process of claim 13 , wherein the effective amount of antibody is in the range of 5 to 20 mg/kg of body weight.

18. The process of claim 13 , wherein the effective amount of vaccine is between about 5 μg per kg of body weight to about 1 gram per kg body weight.

19. The process of claim 13 , wherein the vaccine elicits an immunogenic response to a cancer antigen.

20. The process of claim 7 , wherein the bacterium is selected from the group consisting of E. coli, pneumococcus , and pneumocystis .

21. The process of claim 1 , wherein the animal is a human being.

22. The process of claim 7 , wherein the animal is a human being.

23. The process of claim 13 , wherein the animal is a human being.

24. The process of claim 1 , wherein the effective amount of antibody is in the range of 10 to 20 mg/kg of body weight.

25. The process of claim 7 , wherein the effective amount of antibody is in the range of 10 to 20 mg/kg of body weight.

26. The process of claim 13 , wherein the effective amount of antibody is in the range of 10 to 20 mg/kg of body weight.

27. The process of claim 1 , wherein step (a) is carried out at least 48 hours before step (b).

28. The process of claim 1 , wherein step (a) is carried out at least 72 hours before step (b).

29. The process of claim 7 , wherein step (a) is carried out at least 48 hours before step (b).

30. The process of claim 7 , wherein step (a) is carried out at least 72 hours before step (b).

31. The process of claim 13 , wherein step (a) is carried out at least 48 hours before step (b).

32. The process of claim 13 , wherein step (a) is carried Out at least 72 hours before step (b).

33. The process of claim 1 , wherein the effective amount of vaccine is between about 100 μg per kg of body weight to about 1 gram per kg body weight.

34. The process of claim 1 , wherein the effective amount of vaccine is between about 1 per kg of body weight to about 1 gram per kg body weight.

35. The process of claim 1 , wherein the effective amount of vaccine is between about 10 mg per kg of body weight to about 1 gram per kg body weight.

36. The process of claim 7 , wherein the effective amount of vaccine is between about 100 μg per kg of body weight to about 1 gram per kg body weight.

37. The process of claim 7 , wherein the effective amount of vaccine is between about 1 mg per kg of body weight to about 1 gram per kg body weight.

38. The process of claim 7 , wherein the effective amount of vaccine is between about 10 mg per kg of body weight to about 1 gram per kg body weight.

39. The process of claim 13 , wherein the effective amount of vaccine is between about 100 μg per kg of body weight to about 1 gram per kg body weight.

40. The process of claim 13 , wherein the effective amount of vaccine is between about 1 mg per kg of body weight to about 1 gram per kg body weight.

41. The process of claim 13 , wherein the effective amount of vaccine is between about 10 mg per kg of body weight to about 1 gram per kg body weight.

Assignments (1)
CHANGE OF NAME Recorded Sep 9, 2008
From: MEDIMMUNE, INC.
To: MEDIMMUNE, LLC
Reel/Frame 021501/0319 →
Continuity (5)
Continuation 1119832300 · Aug 8, 2005
Continuation 1040982200 · Apr 9, 2003
Continuation 0979776000 · Mar 2, 2001
Provisional Application 6018656600 · Mar 2, 2000
Related Publication 20080063649A1 · Mar 13, 2008